Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Indicia Production Acquires Biotechnologie Appliquee

Published: Friday, March 22, 2013
Last Updated: Thursday, March 21, 2013
Bookmark and Share
The acquisition strengthens Indicia Production’s ability to subcontract the manufacture of ready-to-use media for microbiological testing.

Indicia Production has announced the acquisition of Biotechnologie Appliquee, based in Taden, in Cotes-d’Armor, France.

The financial terms of this buyout, completed at the end of February, have not been disclosed.

Biotechnologie Appliquee, with a turnover of EUR 500,000 in 2012 and four employees, provides contract manufacturing of ready-to-use media for microbiological testing to the food-processing, pharmaceutical and cosmetic industries.

The company is smaller and more flexible than Indicia Production with extensive expertise in subcontracting. It primarily provides low-volume manufacturing.

This acquisition therefore complements the range of mass-manufactured products from Indicia Production in Lyon.

Indicia Production can now provide contract services for both high and low volume manufacturing and can also respond to client requirements more quickly.

Indicia plans to secure new clients by expanding and diversifying its product range. The company also aims to draw on Biotechnologie Appliquee’s expertise to develop new products throughout 2013.

Ready-to-use culture media are used in the pharmaceutical industry as well as for microbiological diagnostics in food processing and environmental and water monitoring.

They are made from high-quality raw materials and use dehydrated bases selected in accordance with various standards. They are manufactured using advanced technology and are subject to quality testing by approved microbiologists.

“By joining with Indicia, we are able to expand our client base and offer a wider range of products,” said Jean-Yves Horvais, director of Biotechnologie Appliquee.

Horvais continued, “In return, Indicia brings its mass-manufacturing capacities and structured quality assurance. This will allow us to attract new companies within the industry.”

The acquisition enables Indicia Production to strengthen its position as a European leader in the manufacturing of ready-to-use media for microbiological testing.

Indicia is the first subcontractor to manufacture media pouches. The concept was developed at the site 15 years ago.

Biotechnologie Appliquee provides the newly formed company with a better understanding of the raw materials used in these media.

“With this acquisition, we hope to strengthen our production capacities and our subcontracting qualities for both high and low volume manufacturing,” said Stephane Legastelois, president and CEO of Indicia Production.

This buyout is part of Indicia Production’s growth strategy, which began in 2010, including the acquisition of new technologies to increase capacities for filling and sterilizing company media pouches.

Indicia Production, whose turnover reached EUR 5.1 million in 2012, expects a significant increase in profits over the next five years.

“The contract manufacturing market for microbiological testing and aseptic filling is booming. More industry professionals are now choosing to outsource these services in order to reduce their fixed costs,” said Stephane Legastelois. “They are also showing a keen interest in contract services, which we have just strengthened with this acquisition.”

A department manager is expected to join Indicia Production’s on-site team at Biotechnologie Appliquee, in Taden, in the second quarter of 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!